[Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].

Tomohisa Egawa, Takeshi Kemmochi, Tomoyuki Irino, Koki Mihara, Akihiko Okamura, Eiichi Etoh, Yusaku Inaba, Kenki Segami, Yasuhiro Ito, Atsushi Nagashima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Adjuvant chemotherapy with S-1 monotherapy might be insufficient for Stage IIIB highly advanced gastric cancer patients. Our retrospective study was to evaluate the feasibility and safety of adjuvant chemotherapy with S-1 plus docetaxel. S-1 (80 mg/m2) was administered orally for 2 weeks then followed by a 1-week rest period. Docetaxel (40 mg/m2) was simultaneously administered on day 1. The treatment was administered for 1 year and began 6 weeks after D2 curative surgery. Five patients tolerated adjuvant chemotherapy with S-1 plus docetaxel for 1 year (17 courses of treatment). Grade 3/4 hematological toxicities were observed in 10% patients (n=1). Grade 3/4 non-hematological toxicities were observed in 20% patients (n=2). We concluded that S-1 plus docetaxel as adjuvant chemotherapy is a promising strategy for patients with highly advanced gastric cancer.

Original languageEnglish
Pages (from-to)2310-2312
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume39
Issue number12
Publication statusPublished - 2012 Jan 1
Externally publishedYes

Fingerprint

docetaxel
Adjuvant Chemotherapy
Stomach Neoplasms
Retrospective Studies
Safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Egawa, T., Kemmochi, T., Irino, T., Mihara, K., Okamura, A., Etoh, E., ... Nagashima, A. (2012). [Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy, 39(12), 2310-2312.

[Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients]. / Egawa, Tomohisa; Kemmochi, Takeshi; Irino, Tomoyuki; Mihara, Koki; Okamura, Akihiko; Etoh, Eiichi; Inaba, Yusaku; Segami, Kenki; Ito, Yasuhiro; Nagashima, Atsushi.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 39, No. 12, 01.01.2012, p. 2310-2312.

Research output: Contribution to journalArticle

Egawa, T, Kemmochi, T, Irino, T, Mihara, K, Okamura, A, Etoh, E, Inaba, Y, Segami, K, Ito, Y & Nagashima, A 2012, '[Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 39, no. 12, pp. 2310-2312.
Egawa, Tomohisa ; Kemmochi, Takeshi ; Irino, Tomoyuki ; Mihara, Koki ; Okamura, Akihiko ; Etoh, Eiichi ; Inaba, Yusaku ; Segami, Kenki ; Ito, Yasuhiro ; Nagashima, Atsushi. / [Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients]. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2012 ; Vol. 39, No. 12. pp. 2310-2312.
@article{e7bcde8c163742c0b7f16a12a5c4e0c3,
title = "[Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].",
abstract = "Adjuvant chemotherapy with S-1 monotherapy might be insufficient for Stage IIIB highly advanced gastric cancer patients. Our retrospective study was to evaluate the feasibility and safety of adjuvant chemotherapy with S-1 plus docetaxel. S-1 (80 mg/m2) was administered orally for 2 weeks then followed by a 1-week rest period. Docetaxel (40 mg/m2) was simultaneously administered on day 1. The treatment was administered for 1 year and began 6 weeks after D2 curative surgery. Five patients tolerated adjuvant chemotherapy with S-1 plus docetaxel for 1 year (17 courses of treatment). Grade 3/4 hematological toxicities were observed in 10{\%} patients (n=1). Grade 3/4 non-hematological toxicities were observed in 20{\%} patients (n=2). We concluded that S-1 plus docetaxel as adjuvant chemotherapy is a promising strategy for patients with highly advanced gastric cancer.",
author = "Tomohisa Egawa and Takeshi Kemmochi and Tomoyuki Irino and Koki Mihara and Akihiko Okamura and Eiichi Etoh and Yusaku Inaba and Kenki Segami and Yasuhiro Ito and Atsushi Nagashima",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "39",
pages = "2310--2312",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - [Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].

AU - Egawa, Tomohisa

AU - Kemmochi, Takeshi

AU - Irino, Tomoyuki

AU - Mihara, Koki

AU - Okamura, Akihiko

AU - Etoh, Eiichi

AU - Inaba, Yusaku

AU - Segami, Kenki

AU - Ito, Yasuhiro

AU - Nagashima, Atsushi

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Adjuvant chemotherapy with S-1 monotherapy might be insufficient for Stage IIIB highly advanced gastric cancer patients. Our retrospective study was to evaluate the feasibility and safety of adjuvant chemotherapy with S-1 plus docetaxel. S-1 (80 mg/m2) was administered orally for 2 weeks then followed by a 1-week rest period. Docetaxel (40 mg/m2) was simultaneously administered on day 1. The treatment was administered for 1 year and began 6 weeks after D2 curative surgery. Five patients tolerated adjuvant chemotherapy with S-1 plus docetaxel for 1 year (17 courses of treatment). Grade 3/4 hematological toxicities were observed in 10% patients (n=1). Grade 3/4 non-hematological toxicities were observed in 20% patients (n=2). We concluded that S-1 plus docetaxel as adjuvant chemotherapy is a promising strategy for patients with highly advanced gastric cancer.

AB - Adjuvant chemotherapy with S-1 monotherapy might be insufficient for Stage IIIB highly advanced gastric cancer patients. Our retrospective study was to evaluate the feasibility and safety of adjuvant chemotherapy with S-1 plus docetaxel. S-1 (80 mg/m2) was administered orally for 2 weeks then followed by a 1-week rest period. Docetaxel (40 mg/m2) was simultaneously administered on day 1. The treatment was administered for 1 year and began 6 weeks after D2 curative surgery. Five patients tolerated adjuvant chemotherapy with S-1 plus docetaxel for 1 year (17 courses of treatment). Grade 3/4 hematological toxicities were observed in 10% patients (n=1). Grade 3/4 non-hematological toxicities were observed in 20% patients (n=2). We concluded that S-1 plus docetaxel as adjuvant chemotherapy is a promising strategy for patients with highly advanced gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=84875903362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875903362&partnerID=8YFLogxK

M3 - Article

C2 - 23268060

AN - SCOPUS:84875903362

VL - 39

SP - 2310

EP - 2312

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -